Executive analysis
Clear, practical writing for leaders responsible for pharmacy economics, payer relationships, contracting, compliance, reimbursement, and enterprise risk.
Each article explains what the law requires, how it affects pharmacy operations, and what leaders should do next.
Medical Marijuana • Federal Regulation • Controlled Substances
The April rescheduling rule created a federal pathway for specified medical marijuana activity. It did not legalize recreational distribution or use.
Controlled Substances • Pharmacy Operations • Compliance
The expedited federal rule made controls effective August 27. Handlers must align registration, inventory, records, security, and prescribing.
Telemedicine • Controlled Substances • Compliance
OMB is reviewing the final special-registration rule while the temporary prescribing flexibilities approach their December 31 expiration.
Medicare Advantage • False Claims Act • Compliance
Three August settlements show how unsupported diagnoses, retrospective reviews, and risk-sharing payments can expose provider groups to False Claims Act scrutiny.
340B • Reimbursement • Compliance
HRSA’s revised pilot moves selected purchases to post-dispense rebates while a bipartisan Senate bill would end the model and replace it with a clearinghouse.
340B • Federal Policy • Reimbursement
The immediate threat to 340B is not repeal. Federal policy may preserve the program while reducing its financial value and increasing its operating demands.
Compounding • GLP-1 • Compliance
Federal law separates patient-specific preparation, shortage-era copies, and drugs made from ingredients that remain ineligible for compounding.
Compounding • Peptides • FDA
An FDA advisory committee recommendation is a policy signal, not legal authority to compound a bulk drug substance.
FTC Enforcement • PBM • Contracting
The proposed PBM orders offer pharmacies, plan sponsors, lawmakers, and future litigants a practical template for less restrictive commercial terms.
Antitrust • FTC Enforcement • PBM
The FTC’s proposed Express Scripts and Caremark orders reshape pharmacy benefit contracting while leaving its standalone Section 5 theory unresolved.
Antitrust • Algorithmic Pricing • Pharmacy
Two pharmacy reimbursement lawsuits test whether a shared pricing platform or a direct PBM agreement can satisfy Section 1 of the Sherman Act.
Pharmacy Law • Health Policy • Litigation
A source-checked briefing on pharmacy regulation, federal drug policy, enforcement, and litigation developments that leaders should track.
Regulation • Enforcement • Operations
Three August 2026 dates with practical consequences for pharmacy regulation, enforcement, and benefit-plan operations.
PBM • Audit • Reimbursement
Why PBM audit response requires coordinated legal, operational, reimbursement, compliance, and data judgment from the first notice forward.
Contracting • Leadership • Operations
Pharmacy leaders translate contract language into credentialing, claims, documentation, escalation, and accountability before the first dispute arrives.
Explore focused research on PBM audits and appeals, PBM contracts and network access, pharmacy reimbursement and 340B, compounding and FDA compliance, and PBM regulation, ERISA, and competition.